跳至主要内容
临床试验/JPRN-UMIN000008032
JPRN-UMIN000008032招募中2 期

A phase II study of Bevacizumab plus Pemetrexed for previously treated Non Small Cell Lung Cancer with T790M mutation - A phase II study of Bevacizumab plus Pemetrexed for previously treated Non Small Cell Lung Cancer with T790M mutation

Toho University Omori Medical Center0 个研究点目标入组 15 人开始时间: 2012年6月1日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) History of hemoptysis ( >= 2.5mL) 2) History of continuous hemosputum 3) Untreated Brain metastasis 4) Previously treated with Pemetrexed 5) Receiving a blood transfusion, hematopoietic factor, anticoagulant drug 2 weeks prior to enrollment 6)Patients with active severe infections 7) Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) 8) Current or previous history of GI perforation 9) Patients with uncontrollable complications 10) Pregnancy, breast feeding and suspected pregnancy 11) Active concomitant malignancy 12)Inappropriate patients for this study judged by the physicians

研究者

相似试验